Youjun Xu
No. 120 Mailbox, 103 Wenhua Road
Shenyang, 110016, China
Shenyang, 110016, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Nitroreductase-Activated Fluorescent Probes: From Molecular Design to Disease Diagnosis.
Journal: ChemMedChem
Published: February 01, 2026
Pan-EGFR inhibitor targeting EGFR 19del, L858R/T790M and C797S triple-mutations: Design, synthesis, and pharmacological evaluation.
Journal: Bioorganic chemistry
Published: June 19, 2025
Bioorthogonal probes for L-form conversion visualization and insights into antimicrobial resistance.
Bioorthogonal probes for L-form conversion visualization and insights into antimicrobial resistance.
Journal: Chemical science
Published: February 27, 2025
Chemodivergent, enantio- and regioselective couplings of alkynes, aldehydes and silanes enabled by nickel/N-heterocyclic carbene catalysis.
Journal: Science bulletin
Published: September 05, 2024
Design, synthesis, and biological evaluation of Pyrido[1,2-a]pyrimidin-4-one derivatives as novel allosteric SHP2 inhibitors.
Journal: Bioorganic chemistry
Published: May 27, 2024
Natural Amino Acid-Bearing Carbamate Prodrugs of Daidzein Increase Water Solubility and Improve Phase II Metabolic Stability for Enhanced Oral Bioavailability.
Journal: Journal of agricultural and food chemistry
Published: April 03, 2024
Correlation between neutrophil-to-lymphocyte ratio and contrast-induced acute kidney injury and the establishment of machine-learning-based predictive models.
Journal: Renal failure
Published: September 27, 2023
A Mechanism Study on the (+)-ESI-TOF/HRMS Fragmentation of Some PPI Prazoles and Their Related Substances.
Journal: Molecules (Basel, Switzerland)
Published: May 10, 2023
Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 21, 2023
Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFRT790M/L858R inhibitors to treat non-small cell lung cancer.
Journal: Bioorganic & medicinal chemistry
Published: August 04, 2022
Last Updated: 09/26/2026